Corporate calendar for Immuneering Corporation (IMRX): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations.
Price
| Price | $4.45 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (1-5) | 0.64 |
Related companies: ARCT · ASMB · ENTA · FHTX · HUMA · NAUT · PYXS
Explore sector: Healthcare · Biotechnology
More sections of IMRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks